Brainsway Ltd. (TASE:BRIN) today announced success in the clinical trial of its Deep TMS (transcranial magnetic stimulation) for the treatment of depression. Brainsway's share rose 12.3% by early afternoon to NIS 13.90.
56 patients participated in the trial, which was conducted at Hadassah Medical Organization in Jerusalem and Beer Yaakov Mental Health Center. The final results of the safety and effectiveness study found that of the 22 of the 45 patients who completed at least ten treatments showed statistically significant improvement and 13 patients achieved full recovery.
Lire l'intégralité de l'article » (Source: Globes)
Anti-Boycott Israel blog: dépression, traitement dépression par stimulation magnétique transcrânienne